Functionalized Reduced Graphene Oxide as a Versatile Tool for Cancer Therapy

Area of Science:

• Nanomedicine
• Materials Science
• Oncology

Background:

• Traditional cancer therapies face limitations due to side effects and limited efficacy.
• Nanomedicine offers a promising alternative for targeted and effective cancer treatment.
• Carbon-based nanomaterials, particularly reduced graphene oxide (rGO), are emerging as versatile platforms for cancer therapy.

Purpose of the Study:

• To review the synthesis of reduced graphene oxide (rGO) using effective reducing agents.
• To explore the diverse applications of functionalized rGO in various cancer treatment modalities.
• To highlight the potential of rGO-based nanosystems for multimodal cancer therapy.

Main Methods:

• Chemical reduction methods for synthesizing reduced graphene oxide (rGO).
• Functionalization of rGO with therapeutic agents (drugs, siRNA, photosensitizers, ligands).
• Review of studies investigating rGO in chemotherapy, photothermal therapy, gene therapy, and immunotherapy.

Main Results:

• Reduced graphene oxide (rGO) demonstrates excellent photothermal conversion efficiency in the near-infrared range.
• rGO possesses a large surface area ideal for drug loading and functionalization.
• Functionalized rGO enables targeted delivery and stimuli-responsive (temperature/pH) drug/gene release.
• rGO-based systems show potential for multimodal cancer treatment strategies.

Conclusions:

• Functionalized reduced graphene oxide (rGO) is a highly promising nanomaterial for advanced cancer therapy.
• rGO's unique properties facilitate multimodal treatment approaches, including chemotherapy, photothermal therapy, and immunotherapy.
• Further research into rGO-based nanomedicines can lead to improved cancer treatment outcomes with enhanced biocompatibility and targeted delivery.